Anixa Biosciences (NASDAQ:ANIX) Issues Quarterly Earnings Results

Anixa Biosciences (NASDAQ:ANIX) released its earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08), FiscalAI reports.

Anixa Biosciences Stock Performance

NASDAQ ANIX traded down $0.07 during mid-day trading on Wednesday, reaching $2.83. 459,265 shares of the stock were exchanged, compared to its average volume of 192,694. The company has a market capitalization of $96.29 million, a P/E ratio of -9.13 and a beta of 0.51. The business’s 50 day moving average is $3.36 and its 200-day moving average is $2.99. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ANIX shares. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Weiss Ratings downgraded Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.50.

Insider Activity

In other news, CEO Amit Kumar bought 21,000 shares of the stock in a transaction dated Friday, June 12th. The shares were acquired at an average cost of $2.50 per share, with a total value of $52,500.00. Following the purchase, the chief executive officer directly owned 630,812 shares in the company, valued at $1,577,030. The trade was a 3.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have bought 50,024 shares of company stock worth $148,971. Corporate insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds have recently bought and sold shares of the business. Graham Capital Management L.P. acquired a new stake in Anixa Biosciences in the 4th quarter valued at $81,000. Squarepoint Ops LLC acquired a new position in Anixa Biosciences during the fourth quarter worth $83,000. OMERS ADMINISTRATION Corp purchased a new position in Anixa Biosciences during the fourth quarter valued at $95,000. CIBC Private Wealth Group LLC grew its position in shares of Anixa Biosciences by 78.6% in the fourth quarter. CIBC Private Wealth Group LLC now owns 27,865 shares of the company’s stock valued at $87,000 after purchasing an additional 12,265 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Anixa Biosciences during the third quarter worth about $51,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.